These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 12091357)
1. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. McKallip RJ; Lombard C; Fisher M; Martin BR; Ryu S; Grant S; Nagarkatti PS; Nagarkatti M Blood; 2002 Jul; 100(2):627-34. PubMed ID: 12091357 [TBL] [Abstract][Full Text] [Related]
2. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. Do Y; McKallip RJ; Nagarkatti M; Nagarkatti PS J Immunol; 2004 Aug; 173(4):2373-82. PubMed ID: 15294950 [TBL] [Abstract][Full Text] [Related]
3. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572 [TBL] [Abstract][Full Text] [Related]
4. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Hegde VL; Hegde S; Cravatt BF; Hofseth LJ; Nagarkatti M; Nagarkatti PS Mol Pharmacol; 2008 Jul; 74(1):20-33. PubMed ID: 18388242 [TBL] [Abstract][Full Text] [Related]
5. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Paria BC; Ma W; Andrenyak DM; Schmid PC; Schmid HH; Moody DE; Deng H; Makriyannis A; Dey SK Biol Reprod; 1998 Jun; 58(6):1490-5. PubMed ID: 9623610 [TBL] [Abstract][Full Text] [Related]
6. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. Anikwue R; Huffman JW; Martin ZL; Welch SP J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626 [TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. Rao GK; Zhang W; Kaminski NE J Leukoc Biol; 2004 May; 75(5):884-92. PubMed ID: 14966196 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. Rao GK; Kaminski NE J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496 [TBL] [Abstract][Full Text] [Related]
10. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Janoyan JJ; Crim JL; Darmani NA Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518 [TBL] [Abstract][Full Text] [Related]
11. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Klegeris A; Bissonnette CJ; McGeer PL Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211 [TBL] [Abstract][Full Text] [Related]
13. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506 [TBL] [Abstract][Full Text] [Related]
14. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Pertwee RG Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283 [TBL] [Abstract][Full Text] [Related]
15. Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists. Henriquez JE; Crawford RB; Kaminski NE Toxicol Appl Pharmacol; 2019 Apr; 369():82-89. PubMed ID: 30807757 [TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350 [TBL] [Abstract][Full Text] [Related]
17. The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. Valk PJ; Delwel R Leuk Lymphoma; 1998 Dec; 32(1-2):29-43. PubMed ID: 10036999 [TBL] [Abstract][Full Text] [Related]
19. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. McKallip RJ; Lombard C; Martin BR; Nagarkatti M; Nagarkatti PS J Pharmacol Exp Ther; 2002 Aug; 302(2):451-65. PubMed ID: 12130702 [TBL] [Abstract][Full Text] [Related]
20. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs. Reggio PH; Wang T; Brown AE; Fleming DN; Seltzman HH; Griffin G; Pertwee RG; Compton DR; Abood ME; Martin BR J Med Chem; 1997 Sep; 40(20):3312-8. PubMed ID: 9379452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]